PARK CITY, Utah, May 2, 2017 /PRNewswire/ -- InterveneRx is launching its innovative InterV CM+ platform with Allied National,
In partnership with UMass Medical School, InterveneRx will also integrate a clinically enhanced specialty drug prior authorization process during this phase to evaluate its impact on the efficiency and appropriateness of specialty drug approvals.
"We pride ourselves on delivering innovation and best value for our clients, and the results of the InterveneRx program launch will provide us with real outcomes for our clients' specialty drug patients," stated Bill Ashley, CEO of Allied National., Inc.
"We believe the InterveneRx platform fills a significant gap in determining the clinical value and effectiveness of specialty drugs. We are pleased that such a forward thinking company as Allied National, Inc. will be implementing this platform to monitor and manage their specialty drug patients," said IntereveneRx CEO Mark Steck, Pharm D, MBA.
Allied National, Inc. expects to roll the program out to all of its clients nationwide by Q4 2017.
About InterveneVRxInterveneRx is a technology and care management company focused on monitoring and improving complex care for patients utilizing specialty drugs. InterveneRx has developed the first ever automated specialty drug clinical protocols which includes the most comprehensive patient-centered specialty drug database available.
About Allied Health, Inc.Allied National is one of the nation's oldest and most experienced third party administrators. They offer an array of services to agents, covered members and risk-bearing partners including: regulatory compliance; medical underwriting; agent appointment processing; policy issue; premium billing and collection; customer service; claim processing; health care management; and actuarial support.
About the University of Massachusetts Medical SchoolThe University of Massachusetts Medical School has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The mission of the Medical School is to advance the health and well-being of the people of Massachusetts and the world, through pioneering education, research, public service and health care delivery.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/intervenerx-umass-medical-school-and-allied-national-inc-launch-specialty-drug-clinical-management-program-300449723.html
Subscribe to our Free Newsletters!
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...
Hashimoto's thyroiditis is an autoimmune disorder of the thyroid causing hypothyroidism. Synthetic ...
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...View All